Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBD-006
- Development stage
- Unknown
- Lead developer
- Medera
- Modality
- Gene Therapies
01
Overview
MBD-006 is an investigational gene therapy being developed by Medera Biopharmaceutical for the treatment of Peripheral Artery Disease (PAD). The therapy is designed to address vascular insufficiency and impaired blood flow, potentially through the induction of angiogenesis or vascular tissue repair in the affected limbs. MBD-006 is part of Medera's pipeline of disease-modifying therapies discovered and optimized using proprietary platforms, including human-based "mini-heart" models (Myo-Cardia) and synthetic Adeno-associated virus (AAV) Regulatory DNA Sequences (SARDS). The candidate is currently in Phase 1 clinical development, leveraging Medera's expertise in cardiovascular biology and targeted gene delivery.
Beyond the preview
Go deeper on MBD-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBD-006.